Analyze Diet

Topic:Vaccine development

Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
[Route of inoculation and aluminium hydroxide influences in the immunological response of horses vaccinated against equine influenza (author’s transl)].
Arquivos do Instituto Biologico    October 1, 1973   Volume 40, Issue 4 357-368 
Cunha RG, da Silva Passos W, Rodrigues AF.No abstract available
Clinical studies of an attenuated virus cell culture venezuelan equine encephalomyelitis vaccine.
Modern veterinary practice    August 1, 1973   Volume 54, Issue 8 19-22 
Sampson GR, Elliston NG, Miyat JA, Grueter HP, Gillespie JR, Rathmacher RP.No abstract available
[Experience in the preparation and use of inactivated antigens from influenza viruses of different origins].
Voprosy virusologii    July 1, 1973   Volume 18, Issue 4 489-493 
Isachenko VA, Sokolova NN, Shestochenko MA, Zakstel'skaia LIa.No abstract available
Venezuelan equine encephalomyelitis: antibody response in vaccinated horses and resistance to infection with virulent virus.
Journal of the American Veterinary Medical Association    February 15, 1973   Volume 162, Issue 4 280-283 
Jochim MM, Barber TL, Luedke AJ.No abstract available
[Immunization of foals against tetanus toxin. 3. Active immunization of newborn and young foals from specifically pretreated mares].
Archiv fur experimentelle Veterinarmedizin    January 1, 1973   Volume 27, Issue 2 251-262 
Schützler H.No abstract available
Duration of immunity of horses vaccinated with strain TC-83 Venezuelan equine encephalomyelitis virus vaccine. Walton TE, Luedke AJ, Jochim MM, Crenshaw GL, Ferguson JA.No abstract available
Persistence of neutralizing antibody in Equidae vaccinated with Venezuelan equine encephalomyelitis vaccine strain TC-83.
Journal of the American Veterinary Medical Association    October 15, 1972   Volume 161, Issue 8 916-918 
Walton TE, Johnson KM.No abstract available
Effect of back passage of Venezuelan equine encephalomyelitis vaccine (TC-83) on the central nervous system of horses.
Journal of the American Veterinary Medical Association    October 1, 1972   Volume 161, Issue 7 832-833 
Monlux WS, Luedke AJ, Mercado S, Rosales JC, Rios R.No abstract available
Effect of back passage of Venezuelan equine encephalomyelitis vaccine (TC-83) on the central nervous system of horses.
Journal of the American Veterinary Medical Association    October 1, 1972   Volume 161, Issue 7 832-833 
Monlux WS, Luedke AJ, Mercado S, Rosales JC.No abstract available
Central nervous system response of horses to Venezuelan equine encephalomyelitis vaccine (TC-83).
Journal of the American Veterinary Medical Association    August 1, 1972   Volume 161, Issue 3 265-269 
Monlux WS, Luedke AJ, Bowne J.No abstract available
Preparation and evaluation of inactivated Venezuelan equine encephalitis vaccines.
Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B    June 1, 1972   Volume 19, Issue 6 511-517 doi: 10.1111/j.1439-0450.1972.tb00430.x
Mussgay M, Bergold GH, Weiland E, Ueberschär S.No abstract available
Equine abortion (herpes) virus: strain differences in susceptibility to inactivation by dithiothreitol.
Applied microbiology    June 1, 1972   Volume 23, Issue 6 1121-1124 doi: 10.1128/am.23.6.1121-1124.1972
Klingeborn B, Dinter Z.The infectivity of equine abortion (herpes) virus (EAV) was inactivated by treatment with reduced dithiothreitol (DTT). According to their susceptibility to DTT, the EAV strains could be divided into three groups. The vaccine strain RAC-H (419) proved to be more resistant to DTT than all of the other 14 strains tested. The hemagglutinin of EAV was also inactivated by DTT; no strain differences were observed in this respect.
Experimental infection of horses with an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83).
Infection and immunity    May 1, 1972   Volume 5, Issue 5 750-756 doi: 10.1128/iai.5.5.750-756.1972
Walton TE, Alvarez O, Buckwalter RM, Johnson KM.Ten horses (Equus caballus) were vaccinated with strain TC-83 Venezuelan equine encephalomyelitis (VEE) virus vaccine. Febrile responses and leukopenia due to a reduction of lymphocytes and neutrophils were observed in all animals. Viremias were demonstrable in eight horses, with a maximum of 10(3.5) median tissue culture infectious dose units per ml of serum in two horses. Clinical illness with depression and anorexia were observed in five horses. Neutralizing (N), hemagglutination-inhibiting, and complement-fixing antibodies to the vaccine virus were demonstrable by 5, 6.5, and 7 days, respe...
Stability of live attenuated Venezuelan equine encephalitis vaccine.
Applied microbiology    March 1, 1972   Volume 23, Issue 3 654-655 doi: 10.1128/am.23.3.654-655.1972
McManus AT, Robinson DM.Reconstituted Venezulean equine encephalitis vaccine was found to retain significant titers of plaque-forming virus after storage at 4 or 22 C for 24 hr.
Field studies of an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83).
Infection and immunity    February 1, 1972   Volume 5, Issue 2 160-163 doi: 10.1128/iai.5.2.160-163.1972
Eddy GA, Martin DH, Reeves WC, Johnson KM.A series of field studies using strain TC-83 attenuated Venezuelan equine encephalomyelitis vaccine in horses was made to determine the rate of seroconversions, the postvaccination viremia, and the possibility of adverse reactions to the vaccine. The rate of seroconversions varied from 50% in one study to 91 and 100% in two others. The highest level of viremia measured was 7 x 10(3) to 8 x 10(3) plaqueforming units per ml. No adverse reactions to the vaccine were observed in any horses, including 42 pregnant mares and their resulting foals.
Inactivated complement fixing antigen from Venezuelan equine encephalitis virus grown in tissue culture. Gruber J, Birrell D, Wright GG.No abstract available
Safety and efficacy of an attenuated Venezuelan equine encephalomyelitis vaccine for use in Equidae.
Journal of the American Veterinary Medical Association    September 15, 1971   Volume 159, Issue 6 731-738 
Spertzel RO, Kahn DE.No abstract available
Production of antibody against Australia antigen in horses.
Vox sanguinis    June 1, 1971   Volume 20, Issue 6 559-560 doi: 10.1111/j.1423-0410.1971.tb00468.x
Geserick G, Müller G, Schnitzler S, Mix H.No abstract available
Equine influenza immunisation–the role of nasal antibody–a review.
Australian veterinary journal    April 1, 1971   Volume 47, Issue 4 146-148 doi: 10.1111/j.1751-0813.1971.tb02123.x
Rouse BT.No abstract available
Immunogenicity of purified venezuelan equine encephalitis virus inactivated by ionizing radiation.
Infection and immunity    April 1, 1971   Volume 3, Issue 4 574-579 doi: 10.1128/iai.3.4.574-579.1971
Gruber J.Purified and concentrated Venezuelan equine encephalitis (VEE) virus derived from tissue cultures, rendered noninfectious by ionizing radiation with retention of in vitro serological activity, also retained a high level of immunogenicity. In mice, fluid vaccines afforded excellent protection against lethal challenge with homologous Trinidad strain VEE virus. A direct relationship was observed between concentration of vaccine or number of injections and survival. One intraperitoneal inoculation of undiluted vaccine protected essentially all mice challenged 21 days later with 100,000 mouse intra...
[Serologic studies following influenza immunization of horses. II. Reimmunization 1 year after the initial vaccination].
Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B    December 1, 1970   Volume 17, Issue 10 1003-1009 
Pressler K.No abstract available
Immunization of horses against equine infectious anemia (EIA) with an attenuated EIA virus.
National Institute of Animal Health quarterly    January 1, 1970   Volume 10, Issue 3 113-122 
Kono Y, Kobayashi K, Fukunaga Y.No abstract available
Induction of tolerance in man to horse-IgG.
Lancet (London, England)    November 22, 1969   Volume 2, Issue 7630 1141-1142 doi: 10.1016/s0140-6736(69)90744-2
Brendel W, Land W, Hopf U, Seifert J.No abstract available
Enhanced humoral immunity in mice infected with attenuated Venezuelan equine encephalitis virus.
Journal of immunology (Baltimore, Md. : 1950)    October 1, 1969   Volume 103, Issue 4 699-707 
Howard RJ, Craig CP, Trevino GS, Dougherty SF, Mergenhagen SE.No abstract available
[Immunization of horses against rhinopneumonitis (equine virus abortion) with porcine-testicle-cell adapted live virus].
Wiener tierarztliche Monatsschrift    September 1, 1969   Volume 56, Issue 7 275-280 
Kubin G, Kölbl O.No abstract available
Equine piroplasmosis: production of antigens for the complement-fixation test.
American journal of veterinary research    August 1, 1969   Volume 30, Issue 8 1337-1341 
Frerichs WM, Holbrook AA, Johnson AJ.No abstract available
Comments on biologic requirements and control of equine rhinopneumonitis vaccine.
Journal of the American Veterinary Medical Association    July 15, 1969   Volume 155, Issue 2 312-314 
Bittle JL.No abstract available
Biologic requirements and control for equine encephalomyelitis vaccines.
Journal of the American Veterinary Medical Association    July 15, 1969   Volume 155, Issue 2 376-379 
Tamoglia TW.No abstract available
Mixed equine bacterins.
Journal of the American Veterinary Medical Association    July 15, 1969   Volume 155, Issue 2 432 
Phillips CE.No abstract available
The case for an adjuvanted equine influenza vaccine.
Journal of the American Veterinary Medical Association    July 15, 1969   Volume 155, Issue 2 281-284 
Kucera CJ.No abstract available